Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BD9K
|
|||
| Drug Name |
Gilotrif
|
|||
| Synonyms |
Afatinib dimaleate; AFATINIB DIMALEATE; 850140-73-7; Afatinib (diMaleate); UNII-V1T5K7RZ0B; BIBW 2992MA2; Afatinib dimaleate [USAN]; V1T5K7RZ0B; CHEBI:76003; Afatinib (BIBW2992) Dimaleate; Afatinib maleate; Afatinib dimaleate (USAN); Giotrif; Gilotrif (TN); Giotrif (TN); Afatinib maleate (JAN); (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate); BIBW2992 MA2; CHEMBL2105712; USNRYVNRPYXCSP-JUGPPOIOSA-N; MolPort-028-744-902; AOB873
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Squamous cell carcinoma [ICD-11: 2B60-2D01] | Phase 3 | [1] | ||
| Glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 2 | [1] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H33ClFN5O11
|
|||
| Canonical SMILES |
CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
|
|||
| InChI |
1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1
|
|||
| InChIKey |
USNRYVNRPYXCSP-JUGPPOIOSA-N
|
|||
| CAS Number |
CAS 850140-73-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:76003
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.